Display options
Cite
Yu X, Zhang R, Yang T, et al. Alpha-l-fucosidase: a novel serum biomarker to predict prognosis in early stage esophageal squamous cell carcinoma. J Thorac Dis. 2019;11(9):3980-3990doi: 10.21037/jtd.2019.08.92.
Yu, X., Zhang, R., Yang, T., Zhang, M., Xi, K., Lin, Y., Wen, Y., Wang, G., Huang, Z., Zhang, X., & Zhang, L. (2019). Alpha-l-fucosidase: a novel serum biomarker to predict prognosis in early stage esophageal squamous cell carcinoma. Journal of thoracic disease, 11(9), 3980-3990. https://doi.org/10.21037/jtd.2019.08.92
Yu, Xiangyang, et al. "Alpha-l-fucosidase: a novel serum biomarker to predict prognosis in early stage esophageal squamous cell carcinoma." Journal of thoracic disease vol. 11,9 (2019): 3980-3990. doi: https://doi.org/10.21037/jtd.2019.08.92
Yu X, Zhang R, Yang T, Zhang M, Xi K, Lin Y, Wen Y, Wang G, Huang Z, Zhang X, Zhang L. Alpha-l-fucosidase: a novel serum biomarker to predict prognosis in early stage esophageal squamous cell carcinoma. J Thorac Dis. 2019 Sep;11(9):3980-3990. doi: 10.21037/jtd.2019.08.92. PMID: 31656672; PMCID: PMC6790429.
Copy Download .nbib Format: NLM
Share it on

J Thorac Dis. 2019 Sep;11(9):3980-3990. doi: 10.21037/jtd.2019.08.92.

Alpha-l-fucosidase: a novel serum biomarker to predict prognosis in early stage esophageal squamous cell carcinoma.

Journal of thoracic disease

Xiangyang Yu, Rusi Zhang, Tianzhen Yang, Mengqi Zhang, Kexing Xi, Yongbin Lin, Yingsheng Wen, Gongming Wang, Zirui Huang, Xuewen Zhang, Lanjun Zhang

Affiliations

  1. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510275, China.
  2. Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
  3. Department of Pathology, Shenzhen Maternity and Child Healthcare Hospital, Shenzhen 518028, China.
  4. Department of Thoracic Surgery, The First Affiliated Hospital of Jinan University, Guangzhou 510630, China.
  5. Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.

PMID: 31656672 PMCID: PMC6790429 DOI: 10.21037/jtd.2019.08.92

Abstract

BACKGROUND: Alpha-l-fucosidase (AFU) not only detects hepatocellular carcinoma (HCC) early but also is used as a clinical prognostic indicator of several malignant tumors. However, no study has investigated the prognostic significance of AFU in a cohort of patients with esophageal squamous cell carcinomas (ESCCs).

METHODS: A retrospective dataset that included 160 consecutive patients with early stage (pT1N0) ESCC who received surgery between January 2005 and December 2012 was analyzed to identify the prognostic value of serum AFU for overall survival (OS) by using Kaplan-Meier analysis and Cox multivariate regression modeling.

RESULTS: The level of serum AFU ranged from 6.2 to 77.0 U/L with a median of 19.9 U/L, and the best cutoff point for OS was 17.95 U/L. Analysis by Pearson's correlation showed that the levels of serum ALT and GGT were both positively correlated with the level of serum AFU (r=0.403, P<0.001 and r=0.264, P=0.001, respectively). After adjusting for significant factors identified by univariate analysis, the Cox multivariate regression model indicated that a young age (<65 years), no history of alcohol consumption, and a low AFU level (≤17.95 U/L) were still significantly associated with longer OS (P=0.008, 0.004 and 0.017, respectively). The 5-year and 10-year OS rates for patients with high AFU levels

CONCLUSIONS: Compared with other serum biomarkers, AFU showed a better prognostic value for long-term survival in patients with early stage ESCC.

2019 Journal of Thoracic Disease. All rights reserved.

Keywords: Esophageal squamous cell carcinoma (ESCC); alpha-l-fucosidase (AFU); prognosis

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

  1. Int J Oncol. 1996 Oct;9(4):747-54 - PubMed
  2. Asian Pac J Cancer Prev. 2014;15(16):6929-34 - PubMed
  3. Oncotarget. 2015 Aug 28;6(25):21283-300 - PubMed
  4. Chin J Cancer Res. 2018 Aug;30(4):396-405 - PubMed
  5. BMC Cancer. 2017 Aug 14;17(1):544 - PubMed
  6. Esophagus. 2019 Jan;16(1):1-24 - PubMed
  7. Br J Cancer. 2014 Apr 2;110(7):1811-9 - PubMed
  8. Glycobiology. 1993 Aug;3(4):291-6 - PubMed
  9. Oncology. 2003;64(1):36-45 - PubMed
  10. Best Pract Res Clin Gastroenterol. 2015 Dec;29(6):885-93 - PubMed
  11. Dis Esophagus. 2018 Aug 1;31(8):null - PubMed
  12. Glycobiology. 2012 May;22(5):638-48 - PubMed
  13. Crit Rev Clin Lab Sci. 2001 Aug;38(4):263-355 - PubMed
  14. CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32 - PubMed
  15. Tumour Biol. 2014 May;35(5):3953-60 - PubMed
  16. Lancet. 2018 Sep 22;392(10152):1015-1035 - PubMed
  17. N Engl J Med. 2003 Dec 4;349(23):2241-52 - PubMed
  18. Hepatology. 1984 Sep-Oct;4(5):889-92 - PubMed
  19. Tumour Biol. 2016 Feb;37(2):1879-87 - PubMed
  20. Hepatology. 1989 Feb;9(2):249-52 - PubMed
  21. J Cell Biochem. 1988 May;37(1):49-59 - PubMed
  22. Ann Surg Oncol. 2014 Nov;21(12):3802-9 - PubMed
  23. Arab J Gastroenterol. 2012 Mar;13(1):9-13 - PubMed
  24. Adv Exp Med Biol. 1980;132:647-54 - PubMed
  25. Cancer Lett. 1992 Sep 14;66(1):43-8 - PubMed
  26. J Surg Oncol. 2013 Jul;108(1):42-6 - PubMed
  27. Clin Pharmacokinet. 1994 Sep;27(3):216-48 - PubMed
  28. Front Med. 2014 Jun;8(2):135-44 - PubMed

Publication Types